אייברנס טבליות 100 מג

Country: Israel

Language: Hebrew

Source: Ministry of Health

Buy It Now

Active ingredient:

PALBOCICLIB

Available from:

PFIZER PHARMACEUTICALS ISRAEL LTD

ATC code:

L01XE33

Pharmaceutical form:

טבליות מצופות פילם

Composition:

PALBOCICLIB 100 MG

Administration route:

פומי

Prescription type:

מרשם נדרש

Manufactured by:

PFIZER INC, USA

Therapeutic area:

PALBOCICLIB

Authorization date:

2023-06-22

Patient Information leaflet

                                Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
1
" )
(
-
1986
™
75 "
™
100 "
™
125 "
:
75
,"
100
"
125
"
palbociclib 75 mg, 100 mg or 125 mg
:
6
"
"
.
.
.
,
.
.
.
.
18
.
1 .
?
,
-
HER2
,
:
•
)
(
.
•
(
fulvestrant
)
.
:
,
.
2 .
:
•
)
(
(
6
)
.
: ,
:
•
.
,
•
.
•
.
2
"
,
"
.
•
.
2
."
,
"
.
2
,
"
."
18
.
18
.
. , , ,
.
:
•
:
,
)
(
;
,
,
,
(
)
;
/
,
,
,
(
)
;
(
)
;
(
)
.
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
2
•
:
)
(
;
,
(
)
,
St. John's Wort
(
)
,
,)
(
(
)
;
.
•
,
.
.
•
:
(
,)
,
,
(
)
,
(
,
,)
,)
(
,
(
/
,)
(
,)
(
)
.
.
.
,
•
.
.
-
.
.
-
.
-
.
-
,
.
•
.
.
.
.
3
.
.
.
.
.
,
.
3 .
?
.
.
.
:
•
125
"
21
7
,
28
.
•
,
.
.
•
,
500
"
1
,
15
-
29
.
.
• .
•
.
•
:
.
,
/
.
•
.
,
.
,
,
.
.
.
,
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
3 ! . . , .
4 .
,
.
.
.
:
•
( :)
.
,
.
.
,
,
.
.
•
:
.
:
,
,
,
,
.
•
(
)
:
.
.
,
,
.
(≥ 10%) :
,
(
)
,
,
,
,
,
,
,
,
,
,
,
/
,
,
,
(
)
,
.
:
,
,
,
,
,
. , , , .
"
"
(
www.health.gov.il
)
,
"
:
https://sideeffects.health.gov.il
5 .
?
•
!
/
.
.
•
(
exp. date
)
.
.
•
-
30°C
.
.
•
/
/
.
6 .
:
Microcrystalline cellulose, succinic acid, crospovidone, magnesium
stearate, colloidal silicon dioxide,
hypromellose (E464), titanium dioxide (E171), triacetin, indigo
carmine aluminum lake (E132), iron oxide
red (E172) (75 mg and 125 mg tablets only), iron oxide yellow (E172)
(100 mg tablets only).
:
75
:"
,
,
“Pfizer”
,
-
“PBC 75”
.
100
:"
,
,
“
Pfizer
”
,
-
“
PBC 100
”
.
Ibrance tablets, PIL, Israel, CC TC 021123
2023-0088988
4
125
:"
,
,
“Pfizer”
,
-
“PBC 125”
.
21
63
.
.
:
,"
'
9
,
46725
. :
75
:"
173-61-36955-99
100
:"
173-62-36956-99
125
:"
173-63-36957-99
,
.
,
.
-
09/2023
.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet English 08-11-2023
Public Assessment Report Public Assessment Report English 05-12-2023
Patient Information leaflet Patient Information leaflet Arabic 08-11-2023

Search alerts related to this product